Session 10 - Young Investigator Presentations

Dr Arjun K Ghosh MBBS, MSc, PhD, FHEA, FACC, FESC, FRCP, FICOS is a Consultant Cardiologist at Barts Heart Centre (BHC), St. Bartholomew’s Hospital, London and at University College London Hospital (UCLH). He is the first cardiologist in the UK to be appointed specifically in cardio-oncology and helped establish Cardio-Oncology services at both these hospitals which are now amongst the biggest services worldwide. Arjun leads the cardio-oncology service at UCLH. Arjun is also actively involved in developing cardio-oncology curricula and guidelines and changing practice through the British Society of Echocardiography, British Cardio-Oncology Society and International Cardio-Oncology Society and UK Specialist Advisory Committee (SAC). He was joint first author of the first British cardio-oncology guidelines published earlier this year. He runs the UK’s only national Cardio-Oncology Study Day and help organise the only pan-European Cardio-oncology Symposium. Outside of the interesting world of cardiology’s newest subspecialty Arjun is involved in cardiac MRI (CMR) and cardio-oncology echocardiography and has several national and international leadership and management positions at the British Cardiovascular Society, the Royal Society of Medicine, the British Cardio-Oncology Society and the International Cardio-Oncology Society. He is the co-host of the ICOS podcast and has recently been appointed to the ACC Cardio-Oncology Leadership Council. You can find him on Twitter @arjunkg.

Bio: Dr. Guha is an Assistant Professor of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, and a consultant cardiologist in the Harrington Heart and Vascular Institute. He is an expert in cardiovascular epidemiology pertaining to cardio-oncology. Additionally, he is a faculty member of the Harrington Heart and Vascular Insitute's cardio-oncology program. Finally, he is a member of the JACC: Cardio-oncology and ICOS SoMe working groups.

Dr Ruddy is a breast medical oncologist at Mayo Clinic Rochester who co-leads the Symptom Control/Survivorship Cross-Disciplinary Group and the Population Sciences Program for Mayo Clinic Cancer Center across all Mayo Clinic sites. Cardiotoxicity is one of her primary research interests, and she is co-PI of an R01-funded clinical trial assessing carvedilol as a cardioprotectant during Her2-directed therapy for breast cancer. she is a member of the NCCN Survivorship Guidelines Committee, a vice chair of the Symptom Intervention Committee in the Alliance for Clinical Trials in Oncology, and an Associate Editor at JNCI and at JACC Cardio-Oncology.

Richard Cheng, MD, MSc is a HF cardiologist and cardio-oncologist with a focus on education, risk stratification, imaging, and treatment strategies for HF, cardiomyopathies, cardiac amyloidosis and cancer therapy-associated cardiac dysfunction. His recent research interests include the prevention of cardiovascular disease, epidemiology, and long-term cardiovascular complications of cancer treatment in breast cancer survivors and stem cell transplant recipients. He also has ongoing studies focused on risk stratification, multimodality imaging and outcomes in cardiac amyloidosis, cardiomyopathies, heart transplantation and LVAD recipients. He serves on the editorial boards of JACC, JACC: Cardio-Oncology, ACC.org, Heart, and the Journal of Heart and Lung Transplantation.

Dr. Rupal O'Quinn is an Assistant Professor of Clinical Medicine at the University of Pennsylvania, and the Director of Cardio-Oncology at Penn Presbyterian Medical Center. Dr. O’Quinn joined the faculty in 2015, and specializes in the field of cardio-oncology and multi-modality cardiovascular imaging that includes echocardiography and cardiac magnetic resonance. She is currently on the Research and Scientific Advisory Committee of the International Cardio-Oncology Society (ICOS), as well as a member of the Training in Cardio-Oncology and Cardio-Oncology Advocacy workgroups within the American College of Cardiology. Dr. O'Quinn completed a fellowship at the Hospital of the University of Pennsylvania in 2015, where she focused on Cardio-Oncology. Prior to that, Dr. O'Quinn completed a General Cardiology Fellowship at Beth Israel Deaconess Medical Center - Harvard University Medical School in Boston, Massachusetts with a focus in cardiovascular imaging. She is currently pursuing a Master of Healthcare Innovation at the University of Pennsylvania, with expected completion in May, 2023. Dr. O'Quinn completed her residency and chief medical residency at the University of Michigan Health Systems in Ann Arbor, Michigan. She attended medical school at the Rutgers Medical School/University of Medicine and Dentistry of New Jersey, and college at Boston University where she graduated Summa Cum Laude.